Bakhos A. Tannous, PhD

#Thanksgiving is not only to be greatful for all the "good" in our life, but also reflect on the “bad" and recommit our energies to giving thanks and just "#giving". Happy and blessed thanksgiving to everyone who celebrates it

Brain metastasis: From etiology to ecotypes dlvr.it/TLxJTF

The role of ultra-processed food (UPF) in obesity | ⁦@NatureRevEndo⁩ —time to sound the alarm 🚨 on UPF! Nice review that focus on the biological link between UPF and Obesity nature.com/articles/s4157…

Pan-cancer human brain metastases atlas at single-cell resolution dlvr.it/TLw4ZN

In the latest issue! Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis dlvr.it/TLv0mQ

Recent research found that #temozolomide rechallenge is a common, safe, and effective second-line option for patients with MGMT-methylated, #IDHwildtype #GBM following first-line lomustine/temozolomide therapy. Read the full article in our latest issue: bit.ly/4497BUq

Policy Corner by Abdullah H. Ishaque, MD, PhD (@ahishaque), @AbdiAidid, JD, LLM, and @gelarehzadeh, MD, PhD: Lessons from the Failure of Canada’s Artificial Intelligence and Data Act nejm.ai/4ekfI3Q #AIinMedicine

Super excited to share our newest piece out today @NatureRevCancer linking age-induced metabolic reprogramming to cancer development. nature.com/articles/s4156…

🟡 July is #sarcomaawarenessmonth 🟡 Sarcoma is a rare and often overlooked cancer, but its impact is deeply felt by every patient and family it touches. @AstraZeneca and @AlexionPharmaUS, we are committed to transforming outcomes for patients with rare cancers like #sarcoma

The more potent and bespoke immunotherapy vs cancer, the better. Today's example is a neoantigen vaccine vs melanoma cell.com/cell/fulltext/…

Online Now: KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer dlvr.it/TLrhCk

Excited to lead efforts across discovery and clinical strategy to bring therapies for patients with rare cancers where the need is great and the impact can be life-changing. It’s an honor to join a team so dedicated to advancing science and making a real difference for patients

I'm happy to share that I’ve started a new position as Executive Director, Head of Rare Cancer Discovery @AstraZeneca and @AlexionPharmaUS Looking forward to what’s ahead!

Online now: Niche-specific therapeutic targeting of myeloid cells in the central nervous system dlvr.it/TKYNlp

Good update of recommendation for LGG management in the era of vorssidenib. More trials in progress @EANOassociation @EORTC @SapienzaRoma @ESTRO_RT @myESMO

“I see death’s random strikes, who it strikes, it slays and who it misses will to old age live out his days”—Zuhayr bin Abī Sulma (520-609 AD).

Brain tumors don't discriminate—they impact people of all ages, backgrounds, and walks of life. At #AstraZeneca and #Alexion, we are deeply committed to advancing science and innovation in the fight against brain tumors.

May is Brain Tumor Awareness Month. Every year, thousands of individuals are affected by brain tumors. This month, we honor the strength of patients, the dedication of caregivers, and the tireless work of medical professionals and researchers fighting for a cure.

A groundbreaking case study that may redefine GBM immunotherapy! The first report on upfront neoadjuvant administration of #immunecheckpoint inhibitors in #GBM followed by tumor resection. Patient remains recurrence-free after 17months. nature.com/articles/s4159…

We proudly stand with the rare disease community, highlighting their resilience and inspiring our continued efforts to tackle the long diagnosis timeline and life-changing treatments. #RareDiseaseDay